Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fruquintinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 17/20 | 1.00 |
| ▸ | FLT1 known ✓ | P17948 | 1/20 | 1.00 |
| ▸ | FLT4 known ✓ | P35916 | 1/20 | 1.00 |
| ▸ | MET | P08581 | 4/20 | 0.54 |
| ▸ | AURKA | O14965 | 3/20 | 0.54 |
| ▸ | TEK | Q02763 | 3/20 | 0.54 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.54 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.53 |
| ▸ | CSF1R | P07333 | 1/20 | 0.52 |
| ▸ | BRAF | P15056 | 2/20 | 0.51 |
| ▸ | RAF1 | P04049 | 1/20 | 0.51 |
| ▸ | RET | P07949 | 1/20 | 0.50 |
| ▸ | KIF5B | P33176 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fruquintinib SCHEMBL947183 | 1.00 | KDR (1.00) | KDRFLT1FLT4METAURKA | |
| Fruquintinib SCHEMBL29516397 | 1.00 | KDR (1.00) | KDRFLT1FLT4METAURKA | |
| SCHEMBL12909830 | 0.93 | KDR (0.87) | KDRFLT1FLT4METAURKA | |
| SCHEMBL945594 | 0.91 | KDR (0.83) | KDRFLT1FLT4METAURKA | |
| SCHEMBL11931698 | 0.91 | KDR (0.83) | KDRFLT1FLT4METAURKA | |
| SCHEMBL11931690 | 0.90 | KDR (0.81) | KDRFLT1FLT4METAURKA | |
| SCHEMBL30753475 | 0.89 | KDR (0.79) | KDRFLT1FLT4 | |
| SCHEMBL30753458 | 0.89 | KDR (0.79) | KDRFLT1FLT4 | |
| SCHEMBL30753470 | 0.89 | KDR (0.79) | KDRFLT1FLT4 | |
| SCHEMBL943909 | 0.88 | KDR (0.79) | KDRFLT1FLT4METAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 773 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260130856-A1 | LIPOSOME COMPOSITIONS FOR DELIVERY OF COMPOUNDS AND METHODS THEREOF | NANOTECH PHARMA INC (US) | 2026-05-14 | — | — | US | claimed |
| EP-4741395-A1 | NOVEL COMPOUND SENSITIVE TO NITROGEN MONOXIDE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Omniamed Co. Ltd (KR) | 2026-05-13 | — | — | EP | claimed |
| US-12624009-B2 | Hydrate of VEGFR inhibitor, crystal form thereof and preparation method therefor | CHENGDU EASTON BIOPHARMACEUTICALS CO., LTD (CN) | 2026-05-12 | — | — | US | claimed |
| WO-2026090174-A1 | COMPOSITIONS FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS AND METHODS FOR THE SYNTHESIS AND USE THEREOF | BRYET US, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4729510-A1 | INDOLE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Suzhou Merna Therapeutics Co. Ltd (CN) | 2026-04-22 | — | — | EP | claimed |
| EP-4694911-A2 | ADMINISTRATION OF A BETA-CATENIN ANTAGONIST AND METHODS OF USE | Sapience Therapeutics, Inc. (US) | 2026-02-18 | — | — | EP | claimed |
| US-20260021149-A1 | METHOD FOR TREATMENT OF TUMOR BY USING RECOMBINANT ONCOLYTIC VIRUS IN COMBINATION WITH SMALL-MOLECULE ANTICANCER DRUG | JOINT BIOSCIENCES SH LTD (CN) | 2026-01-22 | — | — | US | claimed |
| US-20250388552-A1 | HYDRATE OF VEGFR INHIBITOR, CRYSTAL FORM THEREOF AND PREPARATION METHOD THEREFOR | CHENGDU EASTON BIOPHARMACEUTICALS CO LTD (CN) | 2025-12-25 | — | — | US | claimed |
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | ZOUNEK ALEX (DE) | 2025-12-18 | — | — | US | claimed |
| EP-4663205-A1 | POLYMER-DRUG CONJUGATE, INTERMEDIATE THEREOF, AND USE THEREOF | Shanghai Best-Link Bioscience, LLC (CN) | 2025-12-17 | — | — | EP | claimed |
| US-20220125789-A1 | PHARMACEUTICAL PREPARATION OF FRUQUINTINIB AND USE THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2022-04-28 | — | — | US | claimed |
| EP-3973963-A1 | QUINOLINE DERIVATIVES FOR TREATMENT OF HEAD AND NECK CANCER | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2022-03-30 | — | — | EP | claimed |
| EP-3973964-A1 | QUINOLINE DERIVATIVE USED FOR COMBINATION TREATMENT OF SMALL CELL LUNG CANCER | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2022-03-30 | — | — | EP | claimed |
| EP-3967310-A1 | QUINOLINE DERIVATIVE USED FOR SOFT TISSUE SARCOMA COMBINATION THERAPY | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-03-16 | — | — | EP | claimed |
| EP-3964217-A1 | USE OF COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT, DIMER OR TRIMER THEREOF IN PREPARATION OF DRUG FOR TREATING CANCER | Newish Technology (Beijing) Co., Ltd. (CN) | 2022-03-09 | — | — | EP | claimed |
| EP-3957329-A1 | COMPOSITION FOR TREATING CANCER, APPLICATION THEREOF, AND DRUG | Newish Technology (Beijing) Co., Ltd. (CN) | 2022-02-23 | — | — | EP | claimed |
| EP-3957631-A1 | QUINOLINE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR TREATING EWING'S SARCOMA | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2022-02-23 | — | — | EP | claimed |
| EP-3957310-A1 | COMPOSITION AND USE THEREOF IN PREPARATION OF MEDICATION FOR TREATING CANCER | Newish Technology (Beijing) Co., Ltd. (CN) | 2022-02-23 | — | — | EP | claimed |
| US-11236077-B2 | Fruquintinib eutectic crystal, preparation method therefor, composition, and uses thereof | HANGZHOU SOLIPHARMA CO., LTD. (CN) | 2022-02-01 | — | — | US | claimed |
| CN-113975264-A | Method for preventing or treating side effects of tumor therapy | 上海岸阔医药科技有限公司 | 2022-01-28 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220125789-A1 | PHARMACEUTICAL PREPARATION OF FRUQUINTINIB AND USE THEREOF | FN3K, PFKFB4, PFKFB3 | KDR 348/4885FLT1 164/4885FLT4 180/4885 |
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | KIT, CTSL, PAICS | KDR 328/4885FLT1 160/4885FLT4 392/4885 |
| US-20260130856-A1 | LIPOSOME COMPOSITIONS FOR DELIVERY OF COMPOUNDS AND METHODS THEREOF | SGMS2, SGMS1, LIPA | KDR 1129/4885FLT1 2527/4885FLT4 2932/4885 |
| US-20250388552-A1 | HYDRATE OF VEGFR INHIBITOR, CRYSTAL FORM THEREOF AND PREPARATION METHOD THEREFOR | FLT1, FLT4, KDR | KDR 3/4885FLT1 1/4885FLT4 2/4885 |
| US-12624009-B2 | Hydrate of VEGFR inhibitor, crystal form thereof and preparation method therefor | FLT1, KDR, FLT4 | KDR 2/4885FLT1 1/4885FLT4 3/4885 |
| US-11236077-B2 | Fruquintinib eutectic crystal, preparation method therefor, composition, and uses thereof | MAPK13, BRAF, ME1 | KDR 21/4885FLT1 12/4885FLT4 50/4885 |
| US-20260021149-A1 | METHOD FOR TREATMENT OF TUMOR BY USING RECOMBINANT ONCOLYTIC VIRUS IN COMBINATION WITH SMALL-MOLECULE ANTICANCER DRUG | ERBB2, BTK, ERBB3 | KDR 11/4885FLT1 28/4885FLT4 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.